Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.
- Resource Type
- Article
- Source
- NPJ Vaccines; 7/23/2020, Vol. 5 Issue 1, p1-17, 17p
- Subject
T cells VACCINES IMMUNE response INTERLEUKIN-1 ANTIVIRAL agents - Language
- ISSN
- 20590105